What changed with HRT in 2025, explained in plain English
The short answer
In November 2025 the FDA began removing most of the boxed warning from menopause hormone therapy, dropping the language on heart disease, breast cancer and dementia. The warning about endometrial cancer stays on estrogen-alone products. Hormone therapy is still a personal decision based on your age, timing and history.
What the FDA changed
Since the early 2000s, estrogen products carried the FDA's strongest warning, based largely on the Women's Health Initiative study. In November 2025 the agency began removing the cardiovascular, breast cancer and probable dementia language from that boxed warning. The warning about endometrial cancer remains on systemic estrogen-alone products, which is why women with a uterus take estrogen with a progestogen.
The updated labeling points toward starting systemic therapy before age 60 or within 10 years of menopause. The FDA also announced a generic version of Premarin and a new non-hormonal option for hot flashes.
Why it changed
Critics of the original warning pointed out that the women in the landmark study averaged 63 years old, well past the typical age of menopause, and used a formulation that is less common today. The Menopause Society's 2022 position statement had already concluded that for most healthy women under 60 or within 10 years of menopause, the benefits of hormone therapy outweigh the risks.
Not everyone agreed
Some independent drug-safety reviewers argued the change went further than the available trial data supports. Hormone therapy has real risks for some women, and those risks depend on your age, the type, dose and route, and your personal and family history.
What it means for you
- Hormone therapy is now easier to discuss without fear-driven labeling, but it is still a decision you make with your clinician.
- Patches, gels and sprays carry a lower risk of blood clots and stroke than pills.
- A history of breast cancer, blood clots, stroke, heart disease, liver disease or unexplained bleeding needs a careful conversation.
- Compounded "bioidentical" hormones are not FDA-approved; body-identical estradiol and progesterone are available as approved products.
Bring your questions in writing. Our doctor visit playbook has the exact questions to ask.
Questions
Did the FDA say HRT is completely safe?
No. It removed most of the boxed warning and kept the endometrial cancer warning for estrogen-alone products. Risks still depend on your age, timing, the product and your history.
When did the FDA remove the HRT black box warning?
The FDA announced the change on November 10, 2025.
Want this in one place? Track your symptoms with the free Symptom Snapshot, or get The Sisu Season Guide for the full picture.
Education and personal experience, not medical advice. Talk with your own clinician before making health decisions.
Sources
- FDA scraps boxed warning on menopause hormone therapy (Axios, Nov 10, 2025)
- FDA removes boxed warning from hormone therapies for menopause (Pharmacy Times)
- FDA to remove boxed warnings from hormone therapies (RAPS)
- The Menopause Society, 2022 Hormone Therapy Position Statement (PubMed)
- Highlights of the 2022 hormone therapy statement (HCPLive)
- A critical view of the label change (Worst Pills, Best Pills)